S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB

• O. Al-Sawaf,
• H. Y. Jin,
• C. Zhang,
• Y. Choi,
• S. Balasubramanian,
• S. Robrecht,
• A. Kotak,
• N. Chang,
• A.-M. Fink,
• E. Tausch,
• C. Schneider,
• M. Ritgen,
• K.-A. Kreuzer,
• B. Chyla,
• J. Paulson,
• B. Eichhorst,
• S. Stilgenbauer,
• Y. Jiang,
• M. Hallek,
• K. Fischer

Affiliations

O. Al-Sawaf

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

H. Y. Jin

4 Genentech Inc., South San Francisco, CA, United States of America

C. Zhang

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

Y. Choi

4 Genentech Inc., South San Francisco, CA, United States of America

S. Balasubramanian

4 Genentech Inc., South San Francisco, CA, United States of America

S. Robrecht

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

A. Kotak

5 Roche Products Ltd, Welwyn Garden City, United Kingdom

N. Chang

5 Roche Products Ltd, Welwyn Garden City, United Kingdom

A.-M. Fink

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

E. Tausch

6 Department III of Internal Medicine, Ulm University, Ulm

C. Schneider

6 Department III of Internal Medicine, Ulm University, Ulm

M. Ritgen

7 Department II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany

K.-A. Kreuzer

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

B. Chyla

8 AbbVie Inc., North Chicago, IL, United States of America

J. Paulson

4 Genentech Inc., South San Francisco, CA, United States of America

B. Eichhorst

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

S. Stilgenbauer

6 Department III of Internal Medicine, Ulm University, Ulm

Y. Jiang

4 Genentech Inc., South San Francisco, CA, United States of America

M. Hallek

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany

K. Fischer

1 Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany